Givler D, Givler A, Luther PM, Wenger DM, Ahmadzadeh S, Shekoohi S, et al
It is tailored to each patients needs and is monitored by our medical professionals
Kondycja naszej skry czsto wiadczy o kondycji caego naszego organizmu
In small proof-of-concept phase 2 randomized controlled trials (RCTs) in patients with biopsy-confirmed MASH, liraglutide at 1.8 mg/day for 48 weeks (201), semaglutide at 0.4 mg/day for 72 weeks (202), and tirzepatide at 15 mg/week for 52 weeks (203) have been reported to achieve placebo-corrected percentages of participants meeting the criteria for resolution of MASH without worsening fibrosis by 30% (P = 0.019), 42% (P 10%) may lead to diabetes remission (237)
Saab AM, Tacchini M, Sacchetti G, Contini C, Schulz H, Lampronti I, Gambari R, Makhlouf H, Tannoury M, Venditti A, Bianco A, Racagni G (2022) Phytochemical analysis and potential natural compounds against SARS-CoV-2/COVID-19 in essential oils derived from medicinal plants originating from Lebanon
Holistic Approach Our unique approach focuses on prevention and treating the whole person, not just a single ailment
